Animal, Cancer and Comparative Oncology

A special issue of Animals (ISSN 2076-2615).

Deadline for manuscript submissions: closed (30 October 2022) | Viewed by 7156

Special Issue Editors


E-Mail Website
Guest Editor
Targos - A Discovery Life Sciences Company, Kassel, Germany
Interests: comparative pathology; oncological pathology; cancer immunity; biomarker evaluation as well as computational pathology

E-Mail Website
Guest Editor
Targos - A Discovery Life Sciences Company, Kassel, Germany
Interests: oncological pathology; cancer immunity; biomarker evaluation; computational pathology as well as comparative pathology

Special Issue Information

Dear Colleagues,

Animals and humans share the same environment and develop similar types of cancer. Interspecies comparison into the pathophysiology of cancer is of benefit for the fight against cancer in different animal species and in humans. Therefore, the aim of this Special Issue is to gather novel scientific information on animal cancer in the context of comparative pathology, biomarker evaluations, and translational medicine.

Biomarker analyses have evolved as an important tool for cancer diagnosis, prognosis, and treatment. Computational pathology facilitates standardized quantitative biomarker detection and measurements. Detailed knowledge into molecular mechanisms of cancer predisposition, resistance, and transmission forms the biological basis for effective anticancer regimes. Notably, some animal species show natural resistance against cancer, whereas others are severely affected by certain cancer types, including transmissible neoplasms.

We invite you to share your professional expertise on cancer in animals and comparative oncological pathology.

We look forward to receiving your contributions to cancer research in animals comparable to that being conducted in humans.

PD Dr. Sandra Schöniger
Prof. Dr. Bharat Jasani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • animal cancer
  • comparative pathology
  • biomarker analysis
  • computational pathology
  • cancer predisposition
  • resistance
  • transmission

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 4031 KiB  
Article
Pathological Features and Molecular Phenotype of MMTV Like-Positive Feline Mammary Carcinomas
by Francesca Parisi, Luisa Vera Muscatello, Prospero Civita, Francesca Lessi, Michele Menicagli, Francesca Millanta, Barbara Brunetti, Cinzia Benazzi, Giuseppe Sarli, Giulia Freer, Mauro Pistello, Chiara Maria Mazzanti and Alessandro Poli
Animals 2021, 11(10), 2821; https://doi.org/10.3390/ani11102821 - 27 Sep 2021
Cited by 6 | Viewed by 2397
Abstract
In the last few years MMTV-like nucleotide sequences were detected in some feline and canine mammary tumours. Due to the confirmed role of cats in the epidemiology of the MMTV-like virus, the aim of this study was to investigate the main pathological features [...] Read more.
In the last few years MMTV-like nucleotide sequences were detected in some feline and canine mammary tumours. Due to the confirmed role of cats in the epidemiology of the MMTV-like virus, the aim of this study was to investigate the main pathological features of positive feline mammary carcinomas (FMCs). Twenty-four FMCs were collected at the University of Bologna, submitted to laser microdissection and analysed by nested fluorescence-PCR using primer sets specific for MMTV env sequence. For immunohistochemistry, an antibody against MMTV protein 14 (p14) was used. MMTV-like sequences were detected in three out of 24 FMCs (12.5%), one tubular carcinoma, one tubulopapillary carcinoma and one ductal carcinoma. All PCR-positive tumours were also positive for p14. Multiple nucleotide alignment has shown similarity to MMTV ranging from 98% to 100%. All the 102 examined FMCs were submitted to immunohistochemistry for molecular phenotyping. Of the nine MMTV-like positive FMCs, six were basal-like and three luminal-like. Our results demonstrate MMTV-like sequences and protein in FMCs of different geographic areas. Molecular phenotyping could contribute to understand the possible role of MMTV-like virus in FMC tumor biology. Full article
(This article belongs to the Special Issue Animal, Cancer and Comparative Oncology)
Show Figures

Figure 1

Review

Jump to: Research

20 pages, 3863 KiB  
Review
The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
by Sandra Schöniger and Bharat Jasani
Animals 2022, 12(19), 2661; https://doi.org/10.3390/ani12192661 - 4 Oct 2022
Cited by 6 | Viewed by 3886
Abstract
The programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway mainly attracted attention in immuno-oncology, leading to the development of immune checkpoint therapy. It has, however, much broader importance for tissue physiology and pathology. It mediates basic processes of immune tolerance and tissue [...] Read more.
The programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway mainly attracted attention in immuno-oncology, leading to the development of immune checkpoint therapy. It has, however, much broader importance for tissue physiology and pathology. It mediates basic processes of immune tolerance and tissue homeostasis. In addition, it is involved in the pathogenesis of chronic infectious diseases, autoimmunity, and cancer. It is also an important paradigm for comparative pathology as well as the “one health one medicine” concept. The aim of this review is to provide an overview of novel research into the diverse facets of the PD-1/PD-L1 pathway and to give insights into its fine-tuning homeostatic role in a tissue-specific context. This review details early translational research from the discovery phase based on mice as animal models for understanding pathophysiological aspects in human tissues to more recent research extending the investigations to several animal species. The latter has the twofold goal of comparing this pathway between humans and different animal species and translating diagnostic tools and treatment options established for the use in human beings to animals and vice versa. Full article
(This article belongs to the Special Issue Animal, Cancer and Comparative Oncology)
Show Figures

Figure 1

Back to TopTop